首页> 美国卫生研究院文献>Italian Journal of Pediatrics >Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants

【2h】

Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants

机译：意大利帕利珠单抗的成本-效用分析：预防高危早产儿呼吸道合胞病毒感染（RSV）的模拟模型的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

IntroductionThe aim of this study was to assess the cost-utility of palivizumab versus no prophylaxis in the prevention of respiratory syncytial virus infection among high-risk preterm infants.

机译：引言这项研究的目的是评估帕利珠单抗在预防高危早产儿呼吸道合胞病毒感染方面的成本效用与未进行预防的效果。

著录项

期刊名称 Italian Journal of Pediatrics
作者
Gaetano Chirico; Roberto Ravasio; Urbano Sbarigia;
展开▼
作者单位

展开▼
年(卷),期 2020(35),
年度 2020
页码 4
总页数 12
原文格式 PDF
正文语种
中图分类儿科学;
关键词

相似文献

外文文献
中文文献
专利

1. Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants [J] . Gaetano Chirico, Roberto Ravasio, Urbano Sbarigia Italian journal of pediatrics . 2009,第1期

机译：意大利帕利珠单抗的成本-效用分析：预防高危早产儿呼吸道合胞病毒感染（RSV）模拟模型的结果
2. Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants [J] . Gaetano Chirico, Roberto Ravasio, Urbano Sbarigia Italian journal of pediatrics . 2009,第1期

机译：意大利帕利珠单抗的成本-效用分析：预防高危早产儿呼吸道合胞病毒感染（RSV）模拟模型的结果
3. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain [J] . M. Sanchez-Luna, R. Burgos-Pol, I. Oyagüez, BMC Infectious Diseases . 2017,第1期

机译：帕利珠单抗预防早产儿呼吸道合胞病毒感染的成本-效用分析：根据西班牙的临床证据更新
4. Peptide-Functionalized Gold Nanoparticles are Potent Inhibitors of Respiratory Syncytial Virus (RSV) Infection [C] . D. R. Baganizi, S. Bawage, A. Singh, National SBIR/STTR conference;Annual nanotech conference and expo;Annual TechConnect world innovation conference expo . 2016

机译：肽功能化的金纳米粒子是呼吸道合胞病毒（RSV）感染的有效抑制剂。
5. Pediatric Disease Burden Attributable to Respiratory Syncytial Virus (RSV): an application of temporal models and a modified birth-cohort analysis. [D] . Lloyd, Patricia Calderon. 2014

机译：呼吸道合胞病毒（RSV）引起的小儿疾病负担：时态模型的应用和改良的出生队列分析。
6. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain [O] . M. Sanchez-Luna, R. Burgos-Pol, I. Oyagüez, 2017

机译：帕利珠单抗预防早产儿呼吸道合胞病毒感染的成本-效用分析：基于西班牙的临床证据更新
7. Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants [O] . Gaetano Chirico, Roberto Ravasio, Urbano Sbarigia 2009

机译：意大利帕利珠单抗的成本-效用分析：预防高危早产儿呼吸道合胞病毒感染（RSV）的模拟模型的结果

Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants

摘要

著录项

相似文献

相关主题

期刊订阅